FibroBiologics Files S-1 for Public Offering

TL;DR

FibroBiologics just filed an S-1, looks like they're gearing up for an IPO.

AI Summary

FibroBiologics, Inc. filed an S-1 registration statement with the SEC on December 30, 2024, to register securities under the Securities Act of 1933. The company, incorporated in Delaware with its principal executive offices in Houston, Texas, operates in the Pharmaceutical Preparations industry. This filing indicates the company is preparing to offer its securities to the public.

Why It Matters

This S-1 filing signals FibroBiologics, Inc.'s intention to go public, which could provide capital for its operations and research in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As an S-1 filing, it represents a company preparing for an initial public offering, which inherently carries market and execution risks.

Key Numbers

• 2834 — SIC Code (Indicates the company operates in Pharmaceutical Preparations.)
• 86-3329066 — IRS Number (Employer Identification Number for the company.)
• 333-284077 — SEC File Number (Unique identifier for this SEC filing.)

Key Players & Entities

• FibroBiologics, Inc. (company) — Registrant
• Pete O’Heeron (person) — Chief Executive Officer
• Brian Fenske (person) — Legal Counsel (Norton Rose Fulbright US LLP)
• 333-284077 (dollar_amount) — SEC File Number
• 20241230 (date) — Filing Date

FAQ

Key Financial Figures

• $25,000,000 — ckholder. However, we may receive up to $25,000,000 aggregate gross proceeds from sales of
• $2.36 — ted sales price of our common stock was $2.36 per share. Our founder and Chief Execu
• $15 m — forth therein, the principal amount of $15 million, or the Pre-Paid Advance, which w
• $100,000 — 19, 2026 by paying an extension fee of $100,000, and subsequently to February 18, 2026
• $2.41 — version price equal to the lower of (i) $2.41 per share or (ii) 94% of the lowest dai
• $5 million — ber 20, 2024 in the principal amount of $5 million. The second tranche of the Pre-Paid

Filing Documents

• forms-1.htm (S-1) — 665KB
• ex5-1.htm (EX-5.1) — 17KB
• ex10-14.htm (EX-10.14) — 121KB
• ex10-15.htm (EX-10.15) — 22KB
• ex23-2.htm (EX-23.2) — 5KB
• ex107.htm (EX-FILING FEES) — 18KB
• formdrs_001.jpg (GRAPHIC) — 5KB
• formdrs_003.jpg (GRAPHIC) — 202KB
• pg41-76_001.jpg (GRAPHIC) — 4KB
• ex5-1_001.jpg (GRAPHIC) — 8KB
• ex5-1_002.jpg (GRAPHIC) — 7KB
• ex10-15_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-052400.txt ( ) — 1165KB

RISK FACTORS

RISK FACTORS 12 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 14 MARKET AND INDUSTRY DATA 15 TRADEMARKS, SERVICE MARKS AND TRADENAMES 15

USE OF PROCEEDS

USE OF PROCEEDS 15 DIVIDEND POLICY 16 CAPITALIZATION 17 PRINCIPAL AND SELLING STOCKHOLDERS 17 DESCRIPTION OF OUR SECURITIES 19 SHARES ELIGIBLE FOR FUTURE SALE 23 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 24 PLAN OF DISTRIBUTION 27 LEGAL MATTERS 29 EXPERTS 29 WHERE YOU CAN FIND ADDITIONAL INFORMATION 29 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 29 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor Yorkville have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor Yorkville take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Yorkville is offering to sell, and seeking offers to buy, shares of our common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor Yorkville have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by Yorkville and the distribution of this prospectu

View Full Filing

View this S-1 filing on SEC EDGAR